lesogaberan
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
During preclinical and early phase clinical studies of drug candidates, exposure to metabolites should be monitored to determine…
agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study…
1. In this study, hydrophilic interaction liquid chromatography (HILIC), radiochemical activity monitoring and linear trap…
To cite: Shaheen NJ, Denison H, Björck K, et al. Gut 2013;62:1248–1255. ABSTRACT Objective Lesogaberan (AZD3355) is a novel…
OBJECTIVES:Approximately 20–30% of patients with gastroesophageal reflux disease (GERD) do not experience complete symptom…
Lesogaberan is a potent gamma amino butyric acid agonist and has been evaluated for its utility in treatment of gastroesophageal…
AbstractObjective: The aim of this study was to evaluate the pharmacokinetic profile of lesogaberan in healthy subjects after…
Importance of the field: Despite the clinical success of proton pump inhibitors to treat gastroesophageal reflux disease (GERD…
Lesogaberan, under development by AstraZeneca plc, is a GABA(B) agonist for the potential treatment of gastroesophageal reflux…